Results 31 to 40 of about 1,218 (152)

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study)

Journal of Diabetes Investigation, 2020
Aims/Introduction This subanalysis aimed to assess the safety and effectiveness of tofogliflozin by using data from the Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly to categorize elderly ...
Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi, Kazunori Utsunomiya   +6 more
doaj   +1 more source

Multicenter, Open Label, Randomized Controlled Superiority Trial for Availability to Reduce Nocturnal Urination Frequency: Study Protocol for a TOP-STAR Study

Diabetology, 2022
Nocturia is a common disease in patients with type 2 diabetes mellitus that can reduce the quality of life. Sodium glucose co-transporter 2 (SGLT2) inhibitors increase the urine volume and are often discontinued when polyuria occurs, although ...
Hanako Nakajima, Hiroshi Okada, Akinori Kogure, Takafumi Osaka, Takeshi Tsutsumi, Toru Tanaka, Goji Hasegawa, Shinichi Mogami, Kazuteru Mitsuhashi, Noriyuki Kitagawa, Yoshitaka Hashimoto, Miho Yano, Muhei Tanaka, Akane Kitamura, Michiyo Ishii, Naoto Nakamura, Akio Kishi, Emi Ushigome, Masahide Hamaguchi, Michiaki Fukui   +19 more
doaj   +1 more source

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin [PDF]

Diabetes, Obesity and Metabolism, 2018
An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium‐glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log
Motoshi Ouchi, Kenzo Oba, Kohei Kaku, Hideki Suganami, Akihiro Yoshida, Yasunori Fukunaka, Promsuk Jutabha, Asuka Morita, Naoyuki Otani, Keitaro Hayashi, Tomoe Fujita, Tatsuya Suzuki, Masahiro Yasutake, Naohiko Anzai   +13 more
openaire   +2 more sources

Effects of Tofogliflozin on Cardiac Function in Elderly Patients With Diabetes Mellitus

Journal of Clinical Medicine Research, 2020
Patients with type 2 diabetes mellitus (T2DM) are at increased risk for impairments in diastolic relaxation and heart failure with preserved ejection fraction (EF). Recent clinical data suggest that several sodium glucose transporter-2 (SGLT2) inhibitors are found to reduce cardiovascular disease (CVD) events in elderly diabetic patients, but the ...
Higashikawa, Toshihiro, Ito, Tomohiko, Mizuno, Takurou, Ishigami, Keiichirou, Kohori, Masaru, Mae, Kunihiro, Usuda, Daisuke, Takagi, Susumu, Sangen, Ryusho, Saito, Atsushi, Iguchi, Masaharu, Kasamaki, Yuji, Fukuda, Akihiro, Kanda, Tsugiyasu, Okuro, Masashi   +14 more
openaire   +3 more sources

The Influence of Tofogliflozin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes Therapy, 2021
Treatment-related quality of life (QOL) is an important aspect of diabetes management. We evaluated the influence of a sodium-glucose cotransporter 2 (SGLT2) inhibitor, tofogliflozin, on treatment-related QOL in Japanese patients with type 2 diabetes mellitus (T2DM).This is the prespecified subanalysis study of the "Using TOfogliflozin for Possible ...
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, I. Hayashi, M. Tsugawa, H. Yokoyama, H. Yoshii, K. Komiyama, T. Mita, T. Shimizu, T. Yamamoto, S. Kawashima, T. Nakamura, S. Kamei, T. Kinoshita, M. Shimoda, K. Maeda, K. Kosugi, H. Yoshii, H. Ishida, T. Osonoi, M. Saito, A. Tamazawa, S. Sumitani, N. Fujiki, Y. Fujita, S. Shimizu, Y. Umayahara, K. Kato, Y. Irie, R. Kataoka, T. Yasuda, Y. Kiyohara, M. Ohashi, K. Ryomoto, Y. Takahi, Y. Fujishima, Y. Fujita, A. Fukuhara, K. Fukui, Y. Hosokawa, A. Imagawa, H. Iwahashi, K. Mukai, N. Katakami, T. Katsura, D. Kawamori, T. Kimura, S. Kobayashi, J. Kozawa, F. Kubo, N. Maeda, T. Matsuoka, K. Miyashita, S. Nakata, H. Ninomiya, H. Nishizawa, Y. Okuno, M. Otsuki, F. Sakamoto, S. Sasaki, I. Sato, N. Shimo, I. Shimomura, M. Takahara, T. Takano, A. Tokunaga, S. Uno, M. Yamaoka, S. Yoneda, K. Ohtoshi, T. Shiraiwa, M. Hajime, K. Koikawa, F. Kuno, A. Kurozumi, K. Matsushita, M. Narisawa, K. Tanaka, K. Sugai, Y. Okada, K. Torimoto   +104 more
openaire   +2 more sources

Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study)

Contemporary Clinical Trials Communications, 2020
Background: The incidence of nonalcoholic fatty liver disease (NAFLD) has increased recently and is related to obesity and the associated surge in type 2 diabetes mellitus (DM) and metabolic syndrome diagnoses.
Anna Ozaki, Masato Yoneda, Takaomi Kessoku, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Eiji Sakai, Masataka Taguri, Takeharu Yamanaka, Tomoyuki Iwasaki, Takeo Kurihashi, Satoru Saito, Atsushi Nakajima   +14 more
doaj   +1 more source

Changes in the estimated glomerular filtration rate and predictors of the renal prognosis in Japanese patients with type 2 diabetes: A retrospective study during the 12 months after the initiation of tofogliflozin.

PLoS ONE, 2023
BackgroundThe changes in the estimated glomerular filtration rate (eGFR) and predictors of the renal prognosis were retrospectively assessed over the 12 months after the initiation of tofogliflozin, which has the shortest half-life among sodium-glucose ...
Hiroyuki Ito, Hideyuki Inoue, Takuma Izutsu, Suzuko Matsumoto, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane   +7 more
doaj   +1 more source

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes

Journal of Clinical Medicine Research, 2016
Some patients with type 2 diabetes mellitus (T2DM) on insulin have poor glycemic control and require add-on therapy to reach target glucose values. Increased insulin doses or the addition of an oral antidiabetic drug (OAD) may improve glycemic control, but many patients fail to achieve target values.
Suzuki, Katsunori, Mitsuma, Yurie, Sato, Takaaki, Anraku, Takumi, Hatta, Mariko   +4 more
openaire   +3 more sources

Tofogliflozin decreases body fat mass and improves peripheral insulin resistance [PDF]

Diabetes, Obesity and Metabolism, 2018
The impact of tofogliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on peripheral glucose uptake in patients with type 2 diabetes mellitus (T2DM) was investigated using the hyperinsulinaemic‐euglycaemic clamp method in a single‐arm, open‐label study. The following variables were compared between before and after tofogliflozin
Ren Matsuba, Ikuro Matsuba, Mototsugu Shimokawa, Yoshio Nagai, Yasushi Tanaka   +4 more
openaire   +2 more sources

Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

Frontiers in Medicine, 2022
ObjectiveTo evaluate the effects of vitamin E, pioglitazone, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with non-alcoholic fatty liver disease (NAFLD).DesignA network meta-analysis.
Qian Luo, Qian Luo, Ruojun Wei, Ruojun Wei, Yuzi Cai, Yuzi Cai, Qihan Zhao, Qihan Zhao, Yuning Liu, Yuning Liu, Wei Jing Liu, Wei Jing Liu   +11 more
doaj   +1 more source